title: How effective are disease-modifying drugs in delaying progression in relapsing-onset ms?
authors: Steven R
authors: SR
authors: Brenner
authors: M G
authors: MG
authors: Brown
authors: S
authors: S
authors: Kirby
authors: C
authors: C
authors: Skedgel
authors: J D
authors: JD
authors: Fisk
authors: T J
authors: TJ
authors: Murray
authors: V
authors: V
authors: Bhan
authors: I S
authors: IS
authors: Sketris
mesh_terms: D004185:Disability Evaluation; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D000068717:Glatiramer Acetate; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D010455:Peptides / Q000627:therapeutic use; D012107:Research Design; D016896:Treatment Outcome
chemical_list: D018696:Neuroprotective Agents; D010455:Peptides; D000068717:Glatiramer Acetate; D007372:Interferons